DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Left Ventricular Hypertrophy Reduction With Statins in Hypertensives Patients (MK0653A-168)

Information source: Fundación Lindavista del Corazón AC
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Hypertension

Intervention: valsartan (Drug); pravastatin (Drug); simvastatin (Drug); ezetimibe (+) simvastatin (Drug)

Phase: Phase 3

Status: Terminated

Sponsored by: Fundación Lindavista del Corazón AC

Official(s) and/or principal investigator(s):
Medical Monitor, Study Director, Affiliation: Merck Sharp & Dohme Corp.


Evaluate pleiotropic effects of simvastatin in hypertensive patients.

Clinical Details

Official title: Left Ventricular Hypertrophy Reduction With Statins in Hypertensives Patients.

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Left Ventricular Hypertrophy Reduction With Statins in Hypertensive Patients


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- Females Or Males Over 18 Years Old

- Patients With Systemic Arterial Hypertension Grade I And II According With The

European Society Of Cardiology

- Left Ventricular hypertrophy Demonstrated By Echocardiography

- Mild To Moderated hypercholesterolemia

- Willing To Participate And Sign The Informed Consent Form (ICF)

Exclusion Criteria:

- Type 1 Or 2 Diabetes Mellitus

- Familiar hypercholesterolemia

- Low Density Lipoprotein-Cholesterol (LDL-C) > 190 mg/dl

- History Of Myocardial Infarction Or Stable Chronic Angina

- Triglycerides >250 mg/dl

Locations and Contacts

Additional Information

Starting date: January 2008
Last updated: August 17, 2013

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017